The global D-dimer testing market size was valued at USD 1.19 billion in 2019 and is estimated to expand at a considerable CAGR during the forecast period, 2021-2028. The growth of market is attributed to rising demand of advanced point-of-care testing, increase incidence rate of respiratory and cardiovascular diseases, and impact of the COVID-19 pandemic outbreak.
D-dimer, also known as fibrin degradation fragment, is a protein fragment occurs in bloodstream when fibrinolysis takes place for breakdown of blood clot formed when injured. During the process of fibrinolysis, the clumps present in blood gets broken down; after completion of degradation, number of clots is remained in blood known as D-dimers. Medical professionals used to carry out d-dimer testing by extracting blood sample by using needle to take specimens for further examination to identify existence of serious blood clot.
D-dimer test is performed when symptoms of blood clotting disorder occurred such as leg pain & swelling, shortness of breathing, nasal congestion, chest pain, and rise in heartbeat, This test is used for diagnosis of various thrombotic disorders such as deep vein thrombosis (DVT) in which clot floats in deep vein of lower legs followed by other organs of body. Pulmonary embolism (PE) is occurred due to obstruction of arteries in respiratory systems and disseminated intravascular coagulation (DIC). As a result, some severe conditions that involve the formation of blood clot to a large extent, which can cause organ failure and stroke due to the obstruction of blood flow to the central nervous system. The test utilises monoclonal antibodies of latex particles incorporated D-dimer that increases the molecular weight of the immuno complexes of the test specimen. The changes observed in turbidity of specimen are examined by photometrical analysers and turbidimetric analysers.
The report on the global D-dimer testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
D-dimer Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Analyzers and Reagents & Consumables), Test Types (Clinical Laboratory Tests and Point-Of-Care Tests), Testing Methods (Enzyme-Linked Immunosorbent Assays, Latex-Enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, and Others), Applications (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, and Others), End-Users (Hospitals, Academic & Research Institutes, Diagnostic Centers, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Siemens Healthcare AG; Bio-Rad Laboratories Inc; Thermo Fisher Scientific; Laboratory Corporation of America Holdings (LabCorp); Arup Laboratories; Diazyme Laboratories, Inc; BioMerieux SA; Sekisui Diagnostics LLC; BioMedica Diagnostics LLC; Becton, Dickinson & Company; Helena Biosciences, and Quidel Corporation |
Based on products, the global D-dimer testing market is bifurcated into analyzers and reagent & consumables. The reagent & consumables segment accounted for a key share of the market in terms of revenue in 2020. Increase selling of reagents and testing kits, wide accessibility of extemporaneous reagents, and emergence of highly sophisticated robotic D-dimer assay are the key factors that expected to expand the segment during the forecast period. However, the analyzers segment is anticipated to expand at a rapid pace during the forecast period owing to reduction in laboratory time along with increasing clinical research that expected to augmentation of market growth.
On the basis of test types, the market is classified into clinical laboratory tests and point-of-care tests. The clinical laboratory tests segment held a major market share in terms of revenue in 2020 and is anticipated to constitute a dominant share of the market in the coming years. The growth of the segment is due to emergence of highly sophisticated D-dimer assays employed for the diagnosis of disseminated intravascular coagulation. Furthermore, the point-of-care tests segment are estimated to exhibit robust growth during the forecast period owing to introduction of various automated methods. The growth of the segment is attributed to excellent design, improved patient care, lesser maintenance charges, reduced risk of errors, and lesser time of diagnosis. The constant efforts of Research & development to develop fast pace point-of-care test are estimated to boost the segment growth.
In terms of testing methods, the global D-dimer testing market is classified into enzyme-linked immunosorbent assay (ELISA), latex-enhanced immunoturbidimetric assays, fluorescence immunoassays, and others. The ELISA segment held a major market share in terms of revenue in 2020. The microplate ELISA is a reference procedure owing to its high sensitivity towards coagulation biological factors. The emerging automated ELISA assays such as VIDAS method is expected to propel the segment growth. Furthermore, the fluorescence immunoassay segment is anticipated to register a high CAGR during the forecast period due to rising demand of automated fluorescence immunoassay method for D-dimer testing. These assays provide accurate results due to its higher sensitivity and employed affordable reagents.
On the basis of applications, the global D-dimer testing market is divided into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. The deep vein thrombosis segment accounted for a dominant market share and is expected to register a robust CAGR during the forecast period. The growth of market is attributed to increasing the incidence of deep vein thrombosis with risk of complications such difficulty in diagnosis and hinder movement of hospitalised patients. Patients undergone various surgeries are at higher risk of deep vein thrombosis, which simultaneously increase admittance in hospitals and drug treatment. These are the key factors that propel the segment growth in the upcoming years.
Based on end-users, the market is segmented into hospitals, academic & research institutes, diagnostic centers, and others. The hospitals segment is accounted for a dominant market share and is expected to represent a major share of the market from 2021 to 2028. The growth of segment is attributed to increasing hospital admittance rate of patients along with enhancement in pulmonary embolism cases across the globe. Furthermore, the diagnostic centers segment is expected to register vigorous CAGR during the forecast period due to low-cost diagnosis and treatment provided by diagnostic centers with enhancement in the patient satisfaction.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in terms of revenue and is projected to account for a key market share in the coming years. The regional market growth is mainly due to wide clinical applications of blood clotting testing stimulated by regulatory bodies that involve in the management of coagulation testing. On the other hand, the market in Asia Pacific is expected to grow at a rapid pace during the forecast period owing to government initiative for awareness of coagulation tests. These initiatives help medical professionals, which ultimately cause increasing demand for d-dimer test in the region.
The global D-dimer testing market has been segmented on the basis of
ProductsSome of the key players competing in the market are F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Siemens Healthcare AG; Bio-Rad Laboratories Inc; Thermo Fisher Scientific; Laboratory Corporation of America Holdings (LabCorp); Arup Laboratories; Diazyme Laboratories, Inc; BioMerieux SA; Sekisui Diagnostics LLC; BioMedica Diagnostics LLC; Becton, Dickinson & Company; Helena Biosciences, and Quidel Corporation.
Many of these key players are actively investing in research & development to develop new technologies and actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe. For instance, in 2017, Abbott Laboratories Inc., announced that it introduced alinity Ci-series. In, April 2019 Diazyme Laboratories introduced its D-dimer assay technique to expand its testing operation.
The global D-dimer testing market has been segmented on the basis of
ProductsSome of the key players competing in the market are F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Siemens Healthcare AG; Bio-Rad Laboratories Inc; Thermo Fisher Scientific; Laboratory Corporation of America Holdings (LabCorp); Arup Laboratories; Diazyme Laboratories, Inc; BioMerieux SA; Sekisui Diagnostics LLC; BioMedica Diagnostics LLC; Becton, Dickinson & Company; Helena Biosciences, and Quidel Corporation.
Many of these key players are actively investing in research & development to develop new technologies and actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe. For instance, in 2017, Abbott Laboratories Inc., announced that it introduced alinity Ci-series. In, April 2019 Diazyme Laboratories introduced its D-dimer assay technique to expand its testing operation.
Some other reports from this category!